Bendamustine: all 237 studies that test it
Page 2 of 3. Open to participants first (24), then studies with results posted, then the rest; newest registration first within each.
- Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT StudyCompletedNCT00877006Phase 3Results posted
- Open Trial of Bendamustine Hydrochloride in Women With Advanced Ovarian CancerCompletedNCT00867503Phase 2Results posted
- Bendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast CancerCompletedNCT00834678Phase 1/2Results posted
- Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic GliomaCompletedNCT00823797Phase 2Results posted
- Bendamustine in Acute Leukemia and MDSTerminatedNCT00790855Phase 1/2Results posted
- Bendamustine HCL in Relapsed and Primary Refractory Hodgkin LymphomaCompletedNCT00705250Phase 2Results posted
- A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular LymphomaCompletedNCT00636792Phase 2Results posted
- Pilot Study of Bortezomib, Bendamustine and Rituximab on Non-Hodgkin's LymphomaCompletedNCT00547534Phase 2Results posted
- Bendamustine and Bortezomib Combination Therapy in Indolent Non-Hodgkin's Lymphoma(NHL)CompletedNCT00426855Phase 1/2Results posted
- Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate CancerWithdrawnNCT06094842Phase 1
- A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular LymphomaActive, not recruitingNCT05551936Phase 1/2
- Zanubrutinib Followed Zanubrutinib Plus FCR / BR in Newly Diagnosed Symptomatic CLL/SLLStatus unknownNCT05287984Phase 2
- Observation of the Efficacy of BAd Regimen in the Treatment of Relapsed and Refractory Multiple MyelomaStatus unknownNCT05006469Phase 3
- Post-transplantation Benadamustine and Cyclophosphamide in Patients With Refractory Myeloid MalignanciesCompletedNCT04943757Phase 2
- Isatuximab and Bendamustine in Systemic Light Chain AmyloidosisWithdrawnNCT04943302Phase 2
- Mesothelin-Specific T-Cells (FH-TCR-Tᴍsʟɴ) for the Treatment of Metastatic Pancreatic Ductal AdenocarcinomaTerminatedNCT04809766Phase 1
- The Efficacy and Safety of Pomalidomide and Bendamustine With Dexamethasone in Relapsed or Refractory Multiple MyelomaStatus unknownNCT04762745Phase 1/2
- Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's MacroglobulinemiaActive, not recruitingNCT04624906Phase 2
- A Study to Evaluate the Efficacy and Safety of Bendamustine Hydrochloride InjectionCompletedNCT04569838Phase 2
- Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLLActive, not recruitingNCT04515238Phase 2
- A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB)WithdrawnNCT04138875Phase 2
- Isatuximab, Bendamustine, and Prednisone in Refractory Multiple MyelomaTerminatedNCT04083898Phase 1
- Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients with Relapsed/refractory CLLCompletedNCT03787264Phase 2
- Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17Active, not recruitingNCT03755804Phase 2
- The Efficacy of Salvage BGD With autoSCT Consolidation in Advanced Classical HL Patients Not Responding to ABVDCompletedNCT03615664Phase 2
- SyB C-0501(Oral Bendamustine) in Patients With Advanced Solid TumorsCompletedNCT03604679Phase 1
- Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLLCompletedNCT03524235Phase 1
- First Line Therapy of Advanced Stage Follicular Lymphoma in Patients < 60 Years Not Eligible fo Standard Immunochemotherapy and in All Patients ≥ 60 YearsCompletedNCT03492775Phase 2
- INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)CompletedNCT03424122Phase 1
- A Phase I Study of Bendamustine and Melphalan Conditioning and Autologous Stem Cell Transplantation for Treatment of Multiple Myeloma and Relapsed/Refractory B-cell Lymphoma in Elderly PatientsActive, not recruitingNCT03352765Phase 1
- A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin's LymphomaCompletedNCT03343652Phase 1/2
- BeEAC Conditioning Regimen in Malignant Lymphoma Subjects With Indications to Autologous Hematopoietic Stem-cell TransplantationStatus unknownNCT03315520Phase 2
- Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)CompletedNCT03039114Phase 1
- Haploidentical BMT With Post-Transplant Cyclophosphamide and BendamustineCompletedNCT02996773Phase 1
- BEB Conditioning Regimen for Autologous Stem-cell Transplantation(ASCT) in Non-Hodgkin's LymphomaStatus unknownNCT02836639Phase 2
- GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory LeukemiaCompletedNCT02799147Phase 1/2
- Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins LymphomaTerminatedNCT02793583Phase 2/3
- CyBeR Association in Relapsed/Refractory DLBCLStatus unknownNCT02758925Phase 2
- Bendamustine Plus Subcutaneous Rituximab in Patients With Diffuse Large B-cell LymphomaStatus unknownNCT02753062Phase 2
- Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCLStatus unknownNCT02747732Phase 2
- Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell LymphomaCompletedNCT02728531Phase 1
- Bendamustine and Rituximab Combination Therapy for Cold Agglutinin DiseaseCompletedNCT02689986Phase 2
- Sequential Regimen of Bendamustin-Debulking Followed by Ofatumumab and Ibrutinib in CLL Patients (CLL2-BIO)CompletedNCT02689141Phase 2
- Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin LymphomaWithdrawnNCT02623920Phase 2
- Bendamustine Plus Brentuximab Vedotin in HL and CD30+ PTCL in First Salvage SettingTerminatedNCT02499627Phase 2
- Hodgkin Lymphoma Treatment With Adcetris and Levact in the Old PatientCompletedNCT02467946Phase 1/2
- Sequential Regimen of Bendamustine-Debulking Followed by CAL-101 and GA101-Induction and -Maintenance in CLL (CLL2-BCG)CompletedNCT02445131Phase 2
- Bendamustine in Combination With Rituximab as a First-line Therapy Followed by Maintenance Therapy With Rituximab in Patients With Follicular LymphomaStatus unknownNCT02423837Phase 3
- Bendamustine Study in Classical Hodgkin Lymphoma Patients Over 60 Treated by Prednisone, Vinblastine and DoxorubicinCompletedNCT02414568Phase 2
- Sequential Regimen of Bendamustine-Debulking Followed by ABT-199 and GA101-Induction and -Maintenance in CLL (CLL2-BAG)CompletedNCT02401503Phase 2
- Sequential Regimen of Bendamustin [B] Followed by GA101 and Ibrutinib [I] in CLL PatientsCompletedNCT02345863Phase 2
- CLLR3: Bendamustine + GA101 (BG) in Relapsed or Refractory CLL Followed by GA101 Maintenance for Responding PatientsStatus unknownNCT02320383Phase 2
- Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple MyelomaWithdrawnNCT02315157Phase 1
- Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic CancerCompletedNCT02240719Phase 1
- Bendamustine, Prednisone and Velcade® for First-line Treatment of Patients With Symptomatic Multiple MyelomaCompletedNCT02237261Phase 2
- Autologous ROR1R-CAR-T Cells for Chronic Lymphocytic Leukemia (CLL)WithdrawnNCT02194374Phase 1
- Carfilzomib With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin LymphomaCompletedNCT02187133Phase 1
- CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin LymphomaTerminatedNCT02168907Phase 1
- CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin LymphomaCompletedNCT02168140Phase 1
- A Phase I, Bioequivalence Study to Evaluate Two Formulations of Bendamustine (BDM) Hydrochloride (HCl) Administered to Cancer PatientsCompletedNCT02162888Phase 1
- Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic LeukemiaActive, not recruitingNCT02153580Phase 1
- Carfilzomib, Bendamustine Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT02095834Phase 1
- BENdamustine at Elevated Dose for Relapsed Follicular Lymphoma in Intensification Therapy and Transplantation (BENEFIT)TerminatedNCT02008006Phase 2
- Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell MalignanciesCompletedNCT02006485Phase 1
- Rituximab Plus Bendamustine as Front Line Treatment in Frail Elderly (>70 Years) Patients With DLBCL: a Phase II Multicenter Study of the FILStatus unknownNCT01990144Phase 2
- A Phase II Study for Patients With Indolent Non-follicular Non-Hodgkin's LymphomaCompletedNCT01929265Phase 2
- Bendamustine Hydrochloride, Clofarabine, and Etoposide in Treating Younger Patients With Relapsed or Refractory Hematologic MalignanciesCompletedNCT01900509Phase 1
- Capecitabine + Bendamustine in Women With Pretreated Locally Advanced or Metastatic Her2-negative Breast CancerCompletedNCT01891227Phase 2
- Bendamustine, Gemcitabine and Vinorelbine (BeGEV) as Induction Therapy in Relapsed/Refractory Hodgkin's Lymphoma PatientsStatus unknownNCT01884441Phase 2
- Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic MalignanciesCompletedNCT01871675Phase 1
- BR in Patients With CLL With Comorbidities and/or Renal DysfunctionCompletedNCT01832922Phase 1
- Bendamustine/Lenalidomide/Rituximab: Combination as a Second-Line Therapy for 1st Relapsed-Refractory MCLCompletedNCT01737177Phase 2
- Bendamustine, Lenalidomide (Revlimid®) and Dexamethasone (BRd) as 2nd-line Therapy for Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT01701076Phase 2
- Drug-drug Interaction Study of Ofatumumab With Bendamustine in Subjects With Indolent B-cell Non-Hodgkin's LymphomaCompletedNCT01691807Phase 1
- Study of Bendamustine, Lenalidomide and Low-dose Dexamethasone, for the Treatment of Patients With Relapsed MyelomaStatus unknownNCT01686386Phase 1/2
- Rituximab and Bendamustine in Very Elderly Patients or Elderly Medically Non Fit Patients With Aggressive B-cell LymphomaCompletedNCT01686321Phase 2
- A Study of Venetoclax in Combination With Bendamustine + Rituximab or Bendamustine + Obinutuzumab in Participants With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia (CLL)CompletedNCT01671904Phase 1
- Bendamustine Hydrochloride Injection for Previously Untreated Chronic Lymphocytic LeukemiaStatus unknownNCT01657955Phase 3
- Bendamustine in Acute Lymphoblastic Leukemia/Lymphoma (ALL)WithdrawnNCT01649622Phase 2
- A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT01594229Phase 1
- Safety and Efficacy Study of Bendamustine to Treat Non-Hodgkin LymphomaStatus unknownNCT01570049Phase 3
- A Safety and Efficacy Trial of a Combination of Bendamustine, Rituximab and Lenalidomide in Patients With Chronic Lymphocytic LeukemiaCompletedNCT01558167Phase 1/2
- Phase II Trial Designed to Determine Efficacy and Safety of Bendamustine+Dexamethasone+Thalidomide in R/R MMCompletedNCT01526694Phase 2
- Brief Chemoimmunotherapy With R+B+M Followed by R in Elderly Patients Advanced Stage Untreated Follicular LymphomaCompletedNCT01523860Phase 2
- Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's LymphomaActive, not recruitingNCT01479842Phase 1
- Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Refractory or Relapsed Indolent Non-Hodgkin LymphomaCompletedNCT01429025Phase 1
- Bendamustine Versus Fludarabine in Chronic Lymphocytic Leukemia (CLL)CompletedNCT01423032Phase 2/3
- A Phase 1/2 Study of Lenalidomide in Combination With Bendamustine in Relapsed and Primary Refractory Hodgkin LymphomaStatus unknownNCT01412307Phase 1/2
- Lenalidomide Plus Bendamustine and Rituximab for Untreated CLL/SLLCompletedNCT01400685Phase 1
- Bendamustine, Bortezomib (Velcade ®) and Prednisone (BVP) in Patients Newly Diagnosed Multiple MyelomaCompletedNCT01376401Phase 2
- Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and LymphomaTerminatedNCT01352312Phase 1
- BRIEF Bendamustine and Rituximab In Elderly FollicularTerminatedNCT01313611Phase 2
- A Trial to Investigate the Efficacy of Bendamustine in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Refractory to Rituximab.TerminatedNCT01289223Phase 3
- Bendamustine and Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma (NHL)WithdrawnNCT01170052Phase 1/2
- Bendamustine Plus Bortezomib Plus Dexamethasone in Relapsed or Refractory Multiple MyelomaCompletedNCT01168804Phase 2
- Bendamustine and Bevacizumab for Advanced CancersCompletedNCT01152203Phase 1
- PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & OfatumumabWithdrawnNCT01131247Phase 2
- Trial of Rituximab, Bendamustine (RB) for Patients With Follicular Lymphoma Refractory or Relapsed After Treatment With R-chemotherapy in First LineStatus unknownNCT01127841Phase 2
- Clinical Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia With a Combination of Bendamustine and OfatumumabTerminatedNCT01125787Phase 2
- Bendamustine Hydrochloride Injection for Initial Treatment of Chronic Lymphocytic LeukemiaCompletedNCT01109264Phase 2